Cargando…

Glycemic control after switching to faster aspart in adults with type 1 diabetes

AIMS: Post-prandial hyperglycemia remains an unmet need in the management of type 1 diabetes (T1D). In randomized trials, faster insulin aspart (FIA) showed modest but significant reductions of glycemic spikes after meals. Whether such benefit is evident in routine clinical practice is unclear. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fadini, G. P., Boscari, F., Falaguasta, D., Ferretto, S., Maran, A., Avogaro, A., Bruttomesso, D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098588/ https://www.ncbi.nlm.nih.gov/pubmed/35103951 http://dx.doi.org/10.1007/s40618-022-01745-2

Ejemplares similares

Effectiveness of adding alarms to flash glucose monitoring in adults with type 1 diabetes under routine care
por: Boscari, Federico, et al.
Publicado: (2022)

Efficacy of telemedicine for persons with type 1 diabetes during Covid19 lockdown
por: Boscari, Federico, et al.
Publicado: (2021)

Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
por: Bode, Bruce W., et al.
Publicado: (2017)

Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives
por: Boscari, Federico, et al.
Publicado: (2021)

Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration
por: Fadini, Gian Paolo, et al.
Publicado: (2020)

Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance
por: Boscari, F., et al.
Publicado: (2021)

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
por: Morieri, Mario Luca, et al.
Publicado: (2020)

A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2016)

Psychological outcomes of evening and night closed‐loop insulin delivery under free living conditions in people with Type 1 diabetes: a 2‐month randomized crossover trial
por: Kropff, J., et al.
Publicado: (2016)

Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes
por: Sciannameo, V., et al.
Publicado: (2021)

Can Faster Aspart Be Used to Optimize Glycemic Control With Insulin Pump Therapy? From Expectations to Lessons Learned After a Year of Use in the United States
por: Aleppo, Grazia, et al.
Publicado: (2022)

Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?
por: Rosinha, Patrícia, et al.
Publicado: (2022)

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
por: Jang, Han Na, et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2016)

Hyperglycemia, glucocorticoid therapy, and outcome of COVID-19
por: Morieri, Mario Luca, et al.
Publicado: (2020)

It Is All in the Blood: The Multifaceted Contribution of Circulating Progenitor Cells in Diabetic Complications
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

A “Slide Rule” to Adjust Insulin Dose Using Trend Arrows in Adults with Type 1 Diabetes: Test in Silico and in Real Life
por: Bruttomesso, Daniela, et al.
Publicado: (2021)

Managing diabetes in diabetic patients with COVID: where do we start from?
por: Avogaro, Angelo, et al.
Publicado: (2021)

How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Fast‐acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose‐lowering effect relative to insulin aspart
por: Shiramoto, Masanari, et al.
Publicado: (2017)

Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
por: Heise, T., et al.
Publicado: (2015)

Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial
por: Heise, Tim, et al.
Publicado: (2016)

Switch-over Study with Fast-acting Insulin Aspart Showing Lower Glycemic Variability in Type 2 Diabetics with Stage 4 Chronic Kidney Disease: A Case Series
por: Roy, Sayak, et al.
Publicado: (2019)

Amelioration of Glucose Control Mobilizes Circulating Pericyte Progenitor Cells in Type 2 Diabetic Patients with Microangiopathy
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study
por: Longato, Enrico, et al.
Publicado: (2021)

Faster bi-stable visual switching in psychosis
por: Killebrew, Kyle W., et al.
Publicado: (2023)

Time-resolved trajectory of glucose lowering medications and cardiovascular outcomes in type 2 diabetes: a recurrent neural network analysis
por: Longato, Enrico, et al.
Publicado: (2022)

Prevalence and impact of diabetes among people infected with SARS-CoV-2
por: Fadini, G. P., et al.
Publicado: (2020)

SUN-LB117 Faster Acting Insulin Aspart in Patients With Gestational Diabetes Mellitus - an Early Experience From India
por: Bhattacharyya, Supratik
Publicado: (2020)

Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study
por: Fadini, Gian Paolo, et al.
Publicado: (2020)

Why diabetes outpatient clinics should not close during pandemic crises
por: Fadini, G. P., et al.
Publicado: (2021)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
por: Poncina, Nicol, et al.
Publicado: (2014)

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2019)

Effect of ultra-rapid insulin aspart on glycemic control in children with type 1 diabetes: the experience of a Portuguese tertiary centre
por: Costa, Cláudia, et al.
Publicado: (2022)

Differential impact of glycemic control and comorbid conditions on the neurophysiology underlying task switching in older adults with type 2 diabetes
por: Embury, Christine M., et al.
Publicado: (2022)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
por: Longato, Enrico, et al.
Publicado: (2020)

Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care
por: Morieri, Mario Luca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m7p3qumvacndmj7f10a0s94o9f